Evidence map›Paper›PMID 30935364›Full record

ArticleBMC bioinformatics2019

Data and knowledge management in translational research: implementation of the eTRIKS platform for the IMI OncoTrack consortium.

Wei Gu, Reha Yildirimman, Emmanuel Van der Stuyft, Denny Verbeeck, Sascha Herzinger, Venkata Satagopam, Adriano Barbosa-Silva, Reinhard Schneider, Bodo Lange, Hans Lehrach and 4 more

Abstract read
In one paragraph

Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wei GuLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Reha YildirimmanAlacris Theranostics GmbH, Berlin, Germany.
Emmanuel Van der StuyftJanssen Pharmaceutica NV, Beerse, Belgium.
Denny VerbeeckJanssen Pharmaceutica NV, Beerse, Belgium.
Sascha HerzingerLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Venkata SatagopamLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Adriano Barbosa-SilvaLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Reinhard SchneiderLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Bodo LangeAlacris Theranostics GmbH, Berlin, Germany.
Hans LehrachAlacris Theranostics GmbH, Berlin, Germany.
Yike GuoData Science Institute, Imperial College London, London, UK.
David HendersonBayer AG, Berlin, Germany. david.henderson@bayer.com.ORCID http://orcid.org/0000-0002-6433-200X
Anthony RoweJanssen Research and Development Ltd, High Wycombe, UK. arowe4@its.jnj.com.
IMI OncoTrack and the IMI eTRIKS consortia

Funding

Innovative Medicines Initiative 115234 OncoTrackInnovative Medicines Initiative 115446 eTRIKSMedical Research Council MR/S003827/1
6 · The paper itself

Abstract

backgroundFor large international research consortia, such as those funded by the European Union's Horizon 2020 programme or the Innovative Medicines Initiative, good data coordination practices and tools are essential for the successful collection, organization and analysis of the resulting data. Research consortia are attempting ever more ambitious science to better understand disease, by leveraging technologies such as whole genome sequencing, proteomics, patient-derived biological models and computer-based systems biology simulations.

resultsThe IMI eTRIKS consortium is charged with the task of developing an integrated knowledge management platform capable of supporting the complexity of the data generated by such research programmes. In this paper, using the example of the OncoTrack consortium, we describe a typical use case in translational medicine. The tranSMART knowledge management platform was implemented to support data from observational clinical cohorts, drug response data from cell culture models and drug response data from mouse xenograft tumour models. The high dimensional (omics) data from the molecular analyses of the corresponding biological materials were linked to these collections, so that users could browse and analyse these to derive candidate biomarkers.

conclusionsIn all these steps, data mapping, linking and preparation are handled automatically by the tranSMART integration platform. Therefore, researchers without specialist data handling skills can focus directly on the scientific questions, without spending undue effort on processing the data and data integration, which are otherwise a burden and the most time-consuming part of translational research data analysis.

Indexed as

Databases, FactualKnowledge ManagementSystems BiologyAnimalsCells, CulturedComputer SimulationDisease Models, AnimalHumansModels, BiologicalProteomicsSoftwareTranslational Research, BiomedicalWhole Genome SequencingXenograft Model Antitumor AssaysData managementOncologyPrecision medicineTranslational medicine

Identifiers

PMID30935364
PMCPMC6444691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.